Found: 7
Select item for more details and to access through your institution.
Continuous immunotherapy beyond progression in clinical practice for small cell lung cancer.
- Published in:
- Thoracic Cancer, 2024, v. 15, n. 15, p. 1271, doi. 10.1111/1759-7714.15308
- By:
- Publication type:
- Article
Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 12, p. 2275, doi. 10.1002/cncr.28048
- By:
- Publication type:
- Article
Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report.
- Published in:
- Journal of Oncology Pharmacy Practice, 2019, v. 25, n. 8, p. 2023, doi. 10.1177/1078155218816777
- By:
- Publication type:
- Article
Prolonged survival of a patient with lung cancer after treatment with S-1, a new oral fluoropyrimidine anticancer drug.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Prolonged survival of a patient with lung cancer after treatment with S-1, a new oral fluoropyrimidine anticancer drug.
- Published in:
- Medical Oncology, 2007, v. 24, n. 1, p. 103, doi. 10.1007/BF02685910
- By:
- Publication type:
- Article
A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001)
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 1, p. 17, doi. 10.1007/s00280-013-2290-y
- By:
- Publication type:
- Article